Sage is a commercial-stage company with a track record of success that is a direct result of our approach to discovery and translation into the clinic and market. Our GABA and NMDA research areas are just the beginning. We are actively seeking innovative opportunities with academia and industry.
At Sage, we:
- think differently about brain health disorders and how we approach the discovery and development of new medicines.
- search for solutions that have the potential to work faster and last longer, to radically—not just incrementally—improve the lives of patients and their families.
- leverage our distinct approach to translational medicines and science to drive efficiency in our drug development approach.
We are pursuing new pathways with the goal of improving brain health. Our depression, neurology and neuropsychiatry franchise programs aim to change how brain health disorders are thought about and treated. Although brain health disorders are our primary focus, we may also evaluate opportunities in adjacent areas of interest. We are committed to growing our portfolio, starting with a robust R&D process evaluating the safety and efficacy of our novel drug candidates with the goal of potentially addressing gaps in available treatment options for debilitating brain health disorders. To rapidly advance our clinical development programs, we design efficient studies to look for profound therapeutic effects, and partnered opportunities will be developed using the same principles.
Our commitment to growing our portfolio includes evaluating opportunities that meet the following criteria:
- Asset stage: preclinical through commercial
- Modality: small molecules are preferred, but we may be opportunistic on biologics with compelling data
- Indications: most brain health disorders representing clear unmet medical needs
We are interested in exploring strategic partnerships that:
In June 2018, Sage and Shionogi entered into a strategic collaboration to develop and commercialize zuranolone (SAGE-217) in major depressive disorder (MDD) and other indications in Japan, Taiwan, and South Korea. The goal of the collaboration is to accelerate development of a potential medicine for patients in key Asian markets.
Sage’s collaboration with Shionogi continues to advance, with Shionogi recently completing a Phase 2 trial with zuranolone (SAGE-217) in Japan in the treatment of MDD. Under terms of collaboration, Shionogi is responsible for all clinical development, regulatory filings and commercialization of zuranolone (SAGE-217) in MDD, and potentially other indications, in Japan, Taiwan and South Korea. Zuranolone (SAGE-217) is an investigational drug and is not approved by any Health Authority.
In November 2020, Sage and Biogen Inc. entered into a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) in major depressive disorder (MDD) and postpartum depression (PPD), as well as SAGE-324 in essential tremor (ET) and other movement disorders.
Sage and Biogen are jointly developing, and, if FDA approved, will jointly commercialize, zuranolone (SAGE-217) and SAGE-324 in the U.S. Biogen has an exclusive license to develop and commercialize zuranolone (SAGE-217) and SAGE-324 outside of the U.S., excluding rights to zuranolone (SAGE-217) in Japan, Taiwan and South Korea. Zuranolone (SAGE-217) and SAGE-324 are investigational drugs and are not approved by any Health Authority.